▲ Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation.
▲ Dabigatran etexilate pharmacokinetics were linear across a wide dosage range. There were no clinically important pharmacokinetic interactions with digoxin (a P-glycoprotein substrate), pantoprazole (a proton-pump inhibitor) or drugs that are substrates and/or inhibitors of hepatic cytochrome P450 enzymes.
▲ In two large, randomized, double-blind trials of the prevention of venous thromboembolism (VTE) in patients undergoing total hip or total knee replacement surgery, orally administered dabigatran etexilate 220 mg/day was noninferior to subcutaneous enoxaparin sodium 40 mg/day for the primary composite endpoint of total VTE events or all-cause mortality during the treatment period.
▲ There were no significant differences between dabigatran etexilate and enoxaparin sodium in major VTE events and VTE-related mortality. Across trials, ≤0.5% of patients experienced a symptomatic pulmonary embolus or died.
▲ Dabigatran etexilate was generally well tolerated. In patients undergoing total hip or total knee replacement surgery, there was no significant difference between dabigatran etexilate and enoxaparin sodium recipients in the incidence of major or minor bleeding.
KeywordsDabigatran Total Knee Replacement Enoxaparin Sodium Dabigatran Etexilate Fondaparinux Sodium
Acknowledgements and Disclosures
The manuscript was reviewed by: D. Bergqvist, Department of Surgery, University Hospital, Kir Kliniken Uppsala, Akademiska Sjukhus, Uppsala, Sweden; A.W. Fox, University of California San Diego and EBD Consulting, Carlsbad, California, USA; B.B. Jilma, Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from any comments received were made on the basis of scientific and editorial merit.
- 1.National Collaborating Centre for Acute Care. National Institute for Health and Clinical Excellence clinical guideline 46: venous thromboembolism. Reducing the risk of venous thrombo-embolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery [online]. Available from URL: http://www.nice.org.uk/Guidance/CG46 [Accessed 2008 May 13]
- 6.Boehringer Ingelheim Limited. Pradaxa: summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2008 May 15]
- 8.van Ryn J, Hauel N, Waldmann L, et al. Dabigatran inhibits both clot-bound and fluid phase thrombin in vitro: effects compared to heparin and hirudin [abstract no. 3998]. Blood 2007; 110(11): 68BGoogle Scholar
- 9.van Ryn J, Kink-Eiband M, Hauel N et al. Effects of dabigatran, a direct thrombin inhibitor, as compared to the direct factor Xa inhibitors, rivaroxaban and apixaban, on tissue factor-induced human platelet aggregation in platelet rich plasma [abstract no. 1884]. Blood 2007; 110(11): 558a. Plus poster presented at the 49th Meeting of the American Society of Hematology; 2007 Dec 8–11; Atlanta (GA)Google Scholar
- 16.Stangier J, Rathgen K, Stahle H, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate in subjects with moderate hepatic impairment [abstract no. P-W-673]. J Thromb Haemost 2007 Aug 6; 5 Suppl. 2Google Scholar
- 18.Stangier J, Stahle H, Rathgen K. Effect of food and pantoprazole on the bioavailability of the direct thrombin inhibitor dabigatran in healthy subjects [abstract no.1612]. J Thromb Haemost 2005; 3 Suppl. 1Google Scholar
- 21.The RE-MOBILIZE writing committee. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. Epub 2008 Apr 14Google Scholar
- 22.European Medicines Agency. CHMP assessment report for Pradaxa. London: European Medicines Agency, 2008; EMEA/174363/2008: 36Google Scholar
- 23.Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005 Jan; 3(1): 103–11PubMedCrossRefGoogle Scholar
- 24.UK Department of Health. Report of the independent expert working group on the prevention of venous thromboembolism in hospitalised patients [online]. Available from URL: http://www.thrombosis-charity.org.uk/cms/images/stories/File/reports/Report%20of%20the%20Expert%20Group%202007.pdf [Accessed 2008 Jun 26]